Journals / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 7

Comparison of estimated GFR equations based on serum cystatin C alone and in combination with serum creatinine in patients with coronary artery disease

Pages
571–576
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the impact of different variables on the GFRCKD-EPI-CysC equation should not be ignored in specific groups, such as CAD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Several new equations (GFRCKD-EPI-cr, GFRCKD-EPI-CysC, GFRCKD-EPI Cr+CysC) are used for the calculation of estimated GFR (eGFR) to evaluate renal function.
📊
Key Findings & Data:These equations explicitly demonstrate the association of coronary artery disease (CAD) and severe renal impairment cases.
💡
Conclusion & Impact:However, the impact of different variables on the GFRCKD-EPI-CysC equation should not be ignored in specific groups, such as CAD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Several new equations (GFRCKD-EPI-cr, GFRCKD-EPI-CysC, GFRCKD-EPI Cr+CysC) are used for the calculation of estimated GFR (eGFR) to evaluate renal function. These equations explicitly demonstrate the association of coronary artery disease (CAD) and severe renal impairment cases. However, these equations are considered insufficient to explain the relation with normal or mildly impaired eGFR and CAD. Our hypothesis was to indicate the inversely proportional relationship of eGFR values, calculated by the different equations, with the presence of CAD in patients with normal or mildly impaired renal function. Methods: Eighty-eight patients who underwent elective coronary angiographic intervention were enrolled into the study. The study population was divided into two groups based on angiographic documents: patients with normal coronary arteries (CAD-) and patients with CAD (CAD +). These patients were stable and decided to implement angiography for the purpose of suspicion about CAD and control. Since it is thought that eGFR equations based on creatinine are inadequate to determine chronic kidney disease (CKD) and overestimate CKD diagnosis, cystatin C-based equations are considered an alternative. Due to the potential effects of inflammatory events of the markers used in equations, patients with diabetes mellitus, severe CKD, and inflammatory bowel disease were excluded from the study. Results: The average age of all participants was 51.93±9.31 (32-65 years); 80.7% (n=71) was male. A statistical difference was found between the CAD (-) group and the CAD (+) group in terms of the variables of age (45.46±8.48 vs. 54.95±8.11, p<0.001), gender (67.9% vs. 86.7%, male, p=0.037), cystatin C values (1.37±0.34 vs. 0.85±0.39, p<0.001), and GFR equations defined by the Chronic Kidney Disease Epidemiology: GFRCKD-EPI-cr (85.86±14.20 vs. 79.45±10.25, p=0.018), GFRCKD-EPI-CysC (58.61±21.87 vs. 100.82±32.00, p<0.001), and GFRCKD-EPI Cr+CysC (68.29±13.49 vs. 90.75±18.34, p<0.001). After adjustment of the variables in multiple regression analyses, only age (OR, 1.199; 95% CI, 1.077 to 1.335, p=0.001), gender (OR, 8.252; 95% CI, 0.223 to 55.659, p=0.030), and the GFRCKD-EPI-CysC equation (OR, 1.059; 95% CI, 1.028 to 1.090, p<0.001) were detected as predictors for presence of CAD. Conclusion: GFR equations based on cystatin C or combined with creatinine may have superiority to GFR equations based on creatinine alone in CAD patients. However, the impact of different variables on the GFRCKD-EPI-CysC equation should not be ignored in specific groups, such as CAD.

🔖

Cite This Article

DOĞANER, Y. Ç., AYDOĞAN, Ü., ROHRER, J. E., AYDOĞDU, A., ÇAYCI, T., BARÇIN, C., SAĞLAM, K. (2015). Comparison of estimated GFR equations based on serum cystatin C alone and in combination with serum creatinine in patients with coronary artery disease. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 7, 571–576. https://ajindex.com/articles/365567

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009
  2. [CrossRef] 2. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012
  3. [CrossRef] 3. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011
  4. [CrossRef] 4. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005
  5. [CrossRef] 5. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney func- tion - Measured and estimated glomerular filtration rate. New Engl J Med 2006
  6. [CrossRef] 6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976
  7. [CrossRef] 7. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008
  8. [CrossRef] 8. Obiols J, Bargnoux AS, Kuster N, Fesler P, Pieroni L, Badiou S, et al. Validation of a new standardized cystatin C turbidimetric assay: evaluation of the three novel CKD-EPI equations in hypertensive patients. Clin Biochem 2013
  9. [CrossRef] 9. Shlipak MG, Weekley CC, Li YM, Hansson LO, Larsson A, Whooley M. Comparison of Cardiovascular Prognosis by 3 Serum Cystatin C Methods in the Heart and Soul Study. Clin Chem 2011
  10. [CrossRef] 10. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008
  11. [CrossRef] 11. Niccoli G, Conte M, Della Bona R, Altamura L, Siviglia M, Dato I, et al. Cystatin C is associated with an increased coronary atheroscle- rotic burden and a stable plaque phenotype in patients with isch- emic heart disease and normal glomerular filtration rate. Atherosclerosis 2008
  12. [CrossRef] 12. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystati